Answers are grounded in this paper and cite their sources.
Although selected older adults with acute myeloid leukemia can benefit from intensive therapies, recent evidences support the use of lower-intensity therapies (hypomethylating agents or low-dose cytarabine) in most of these patients and emphasize the importance of tolerability and quality of life. Individualized approaches to treatment decision-making beyond consideration of chronologic age alone should therefore be considered. One promising strategy is to combine low-intensity treatments with novel agents.
No takes yet. Share an insight, caveat, or question.
Xavier Thomas (2015) studied this question.
Synapse has enriched 7 related papers. Consider them for comparative context: